Uncover Key Insights on Natera Stock

Large-cap Health Care company Natera has moved 2.7% so far today on a volume of 865,482, compared to its average of 1,156,975. In contrast, the S&P 500 index moved 1.0%.

Natera trades -10.3% away from its average analyst target price of $123.41 per share. The 17 analysts following the stock have set target prices ranging from $37.0 to $160.0, and on average have given Natera a rating of buy.

If you are considering an investment in NTRA, you'll want to know the following:

  • Natera has moved 130.4% over the last year, and the S&P 500 logged a change of 23.9%

  • Based on its trailing earnings per share of -3.11, Natera has a trailing 12 month Price to Earnings (P/E) ratio of -35.6 while the S&P 500 average is 27.65

  • NTRA has a forward P/E ratio of -93.0 based on its forward 12 month price to earnings (EPS) of $-1.19 per share

  • Its Price to Book (P/B) ratio is 17.04 compared to its sector average of 3.61

  • Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide.

  • Based in Austin, the company has 3,282 full time employees and a market cap of $13.59 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.